301047 Stock Overview
Provides recombinant protein and antibody reagents for life science researchers worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Sino Biological,Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥64.02 |
| 52 Week High | CN¥92.21 |
| 52 Week Low | CN¥53.51 |
| Beta | 0.79 |
| 11 Month Change | 16.19% |
| 3 Month Change | 6.79% |
| 1 Year Change | -27.56% |
| 33 Year Change | -68.24% |
| 5 Year Change | n/a |
| Change since IPO | -75.34% |
Recent News & Updates
Shareholder Returns
| 301047 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 11.1% | 7.4% | 9.6% |
| 1Y | -27.6% | -23.7% | -12.3% |
Return vs Industry: 301047 underperformed the CN Biotechs industry which returned -23.7% over the past year.
Return vs Market: 301047 underperformed the CN Market which returned -12.3% over the past year.
Price Volatility
| 301047 volatility | |
|---|---|
| 301047 Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.4% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 301047 has not had significant price volatility in the past 3 months.
Volatility Over Time: 301047's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 953 | Zhang Jie | www.sinobiological.com |
Sino Biological,Inc. provides recombinant protein and antibody reagents for life science researchers worldwide. It offers recombinant proteins, antibodies, cDNA clones, kits, and other reagents that are used in the areas of cancer, cardiovascular biology, cell and developmental biology, epigenetics, immunology, neuroscience, signal transduction, and stem cells.
Sino Biological,Inc. Fundamentals Summary
| 301047 fundamental statistics | |
|---|---|
| Market cap | CN¥7.58b |
| Earnings (TTM) | CN¥195.41m |
| Revenue (TTM) | CN¥659.67m |
41.3x
P/E Ratio12.2x
P/S RatioIs 301047 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301047 income statement (TTM) | |
|---|---|
| Revenue | CN¥659.67m |
| Cost of Revenue | CN¥146.14m |
| Gross Profit | CN¥513.53m |
| Other Expenses | CN¥318.12m |
| Earnings | CN¥195.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.55 |
| Gross Margin | 77.85% |
| Net Profit Margin | 29.62% |
| Debt/Equity Ratio | 0% |
How did 301047 perform over the long term?
See historical performance and comparison